Downstream without a NET

ModiQuest B.V. has discovered that its therapeutic mAb against citrullinated histones has the potential to treat autoimmune diseases by inhibiting the formation of neutrophil extracellular traps that play a role in the pathogenesis of autoimmunity. Because it acts on pathways downstream of PAD, the mAb may have fewer side effects than PAD inhibitors already in development.

Last month, ModiQuest spun out Citryll B.V. as a single-asset company to develop the lead therapeutic anti-citrullinated protein antibody (tACPA) for inflammatory diseases such as rheumatoid arthritis (RA)...